Glucagon-Like Peptide 1 (GLP 1)

A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.

Also Known As:

Networked: 1984 relevant articles (204 outcomes, 287 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Holst, Jens J: 48 articles (01/2016 - 01/2002)
2.	Holst, J J: 38 articles (11/2015 - 01/2000)
3.	Drucker, Daniel J: 34 articles (07/2015 - 01/2002)
4.	Vilsbøll, Tina: 29 articles (12/2015 - 09/2003)
5.	Holst, Jens Juul: 25 articles (12/2015 - 11/2002)
6.	Knop, Filip K: 22 articles (10/2015 - 09/2003)
7.	D'Alessio, David A: 22 articles (06/2015 - 12/2002)
8.	Horowitz, Michael: 21 articles (08/2015 - 08/2002)
9.	Bloom, Stephen R: 19 articles (11/2015 - 06/2004)
10.	Seeley, Randy J: 18 articles (01/2015 - 12/2002)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/2007 - "Hypocaloric diet decreased GLP-1 levels in patients with weight loss with a significant improvement in anthropometric parameters and cardiovascular risk factors. " 06/01/2001 - "The effect of GLP-1 on appetite and food intake may be beneficial in weight reduction." 10/01/2014 - "Long-acting glucagon-like peptide-1 (GLP-1) analogs, because they augment β-cell function and promote weight loss, are effective in preventing IGT progression to T2DM. " 01/01/2010 - "GLP-1 agonists are effective in improving glycaemic control and promoting weight loss." 12/15/2004 - "Modest weight loss might be effective for increasing GLP-1 sensitivity to acute stimulation."
2.	Body Weight (Weight, Body) 12/01/2011 - "Analogues of glucagon-like peptide-1 (GLP-1) represent a new therapeutic option for type 2 diabetes, which offer the advantage of combining beneficial effects on metabolic control with a significant reduction in body weight. " 06/01/2011 - "Glucagon-like peptide 1 has also been found to be effective in reducing body weight. " 01/01/2012 - "After intracerebroventricular injection of these GLP-1 MSC capsules in presymptomatic SOD1 (G93A) mice, we assessed possible protective effects by survival analysis, measurement of body weight, daily monitoring and evaluation of motor performance by rotarod and footprint analyses. " 01/01/2015 - "Randomized controlled trials (RCTs) involving GLP-1 RAs were included if they provided information on body weight. " 06/01/2012 - "In this study, we examined the acute and chronic effects of two different GLP-1 analogues with different pharmacokinetic profiles on GE, food intake and body weight. "
3.	Type 2 Diabetes Mellitus (MODY) 12/01/2012 - "GLP-1 analogues have been proven to be effective in the treatment of type 2 diabetes mellitus. " 10/01/2001 - "Taken together, these results show that insertion of Aha after the 7 position in GLP-1 produces an effective, long-acting GLP-1 analog, which may be useful in the treatment of type 2 diabetes mellitus." 06/01/1999 - "GLP-1 has been shown to be an effective medication for treatment of type 2 diabetes mellitus (DM). " 05/01/2014 - "Glucagon-like peptide-1 (GLP-1) is a novel treatment modality for type 2 diabetes mellitus. " 08/01/1998 - "Beta-cell dysfunction was improved by GLP-1 infusion, suggesting that early GLP-1 therapy may preserve beta-cell function in subjects with IGT or mild NIDDM."
4.	Hyperglycemia 03/01/2011 - "After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects. " 01/01/2008 - "Intravenous administration of GLP-1 ameliorates hyperglycemia in patients with T2DM, but an extremely short half-life limits its utility as a therapeutic agent. " 01/01/2015 - "These findings demonstrated that TGR5 activator WB403 effectively promoted GLP-1 release, improved hyperglycemia and preserved the mass and function of pancreatic β-cells, whereas it did not show a significant side effect on gallbladder. " 06/01/2014 - "The authors sought to evaluate the efficacy of an intravenous glucagon-like peptide-1 (GLP-1) infusion, compared with placebo, to mitigate intraoperative hyperglycemia. " 06/01/2015 - "Studies are required to determine the effects of hyperglycemia on gastric emptying with the subcutaneously administered commercially available GLP-1 agonists in patients with type 2 diabetes."
5.	Insulin Resistance 06/01/2015 - "However, within the entire study group, β-cell GLP-1 sensitivity corrected for insulin resistance varied nearly 10-fold. " 05/01/2015 - "The present study demonstrates that GLP-1 increases MVR in rat skeletal muscle and can reverse early stages of high fat diet-induced insulin resistance in vivo." 05/01/2011 - "We found neither a difference in basal or maximal GLP-1 levels nor in insulin resistance between study groups. " 08/01/2007 - "Recently, many studies have shown GLP-1 can improve insulin resistance in peripheral tissues. " 09/01/2015 - "However, although defective GLP-1 secretion has been correlated with insulin resistance, potential direct effects of GCs on GLP-1-producing L-cell function in terms of GLP-1 secretion and apoptosis have not been studied in any greater detail. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	exenatide (Byetta)
4.	liraglutide
5.	Glucagon-Like Peptide 1 (GLP 1)
6.	Incretins
7.	Hormones
8.	Glucagon (Glukagon)
9.	Peptide YY
10.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Bariatric Surgery
3.	Caloric Restriction
4.	Gastrectomy
5.	Gastric Bypass (Roux-en-Y Gastric Bypass)